Development of an allele-specific minimal residual disease assay for patients with juvenile myelomonocytic leukemia

Blood

Volumn 111, Issue 3, 2008, Pages 1124-1127

  Archambeault, Sophie ^a   Flores, Nikki J ^a   Yoshimi, Ayami ^b   Kratz, Christian P ^b   Reising, Miriam ^b   Fischer, Alexandra ^b   Noellke, Peter ^b   Locatelli, Franco ^b   Sedlacek, Petr ^b   Flotho, Christian ^b   Zecca, Marco ^b   Emanuel, Peter D ^c   Castleberry, Robert P ^c   Niemeyer, Charlotte M ^b   Bader, Peter ^b   Loh, Mignon L ^a,c,d,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b European Working Group of Myelodysplastic Syndromes in Childhood   (United States)

^c CHILDREN S ONCOLOGY GROUP   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ALLELE; ARTICLE; BLOOD ANALYSIS; BONE MARROW CELL; CANCER RELAPSE; CHILD; CHIMERA; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE AMPLIFICATION; GENE MUTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; JUVENILE MYELOMONOCYTIC LEUKEMIA; MALE; MINIMAL RESIDUAL DISEASE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

EID: 38949143672     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-06-093302     Document Type: Article

References (15)

1. Arico M, Biondi A, Pui CH. Juvenile myelomonocytic leukemia. Blood. 1997;90:479-488.
2. Emanuel PD, Shannon KM, Castleberry RP. Juvenile myelomonocytic leukemia: molecular understanding and prospects for therapy. Mol Med Today. 1996;2:468-475.
3. Emanuel PD. Juvenile myelomonocytic leukemia. Curr Hematol Rep. 2004;3:203-209.
4. Largaespada DA, Brannan CI, Jenkins NA, Copeland NG. Nf1 deficiency causes Ras-mediated granulocyte-macrophage colony stimulating factor hypersensitivity and chronic myeloid leukemia. Nat Genet. 1996;12:137-143.
5. Braun BS, Tuveson DA, Kong N, et al. Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. Proc Natl Acad Sci U S A. 2004;101:597-602.
6. Chan IT, Kutok JL, Williams IR, et al. Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease. J Clin Invest. 2004;113:528-538.
7. Le DT, Kong N, Zhu Y, et al. Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder. Blood. 2004;103:4243-4250.
8. Mohi MG, Williams IR, Dearolf CR, et al. Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations. Cancer Cell. 2005;7:179-191.
9. Niemeyer CM, Kratz C. Juvenile myelomonocytic leukemia. Curr Treat Options Oncol. 2003;4:203-210.
10. Woods WG, Barnard DR, Alonzo TA, et al. Prospective study of 90 children requiring treatment for juvenile myelomonocytic leukemia or myelodysplastic syndrome: a report from the Children's Cancer Group. J Clin Oncol. 2002;20:434-440.
11. Locatelli F, Nollke P, Zecca M, et al. Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS/EBMT trial. Blood. 2005;105:410-419.
12. Bergstraesser E, Hasle H, Rogge T, et al. Non-hematopoietic stem cell transplantation treatment of juvenile myelomonocytic leukemia: a retrospective analysis and definition of response criteria. Pediatr Blood Cancer. 2007;49:629-633.
13. Yoshimi A, Niemeyer CM, Bohmer V, et al. Chimaerism analyses and subsequent immunologic intervention after stem cell transplantation in patients with juvenile myelomonocytic leukaemia. Br J Haematol. 2005;129:542-549.
14. Clayton SJ, Scott FM, Walker J, et al. K-ras point mutation detection in lung cancer: comparison of two approaches to somatic mutation detection using ARMS allele-specific amplification. Clin Chem. 2000;46:1929-1938.
15. Glaab WE, Skopek TR. A novel assay for allelic discrimination that combines the fluorogenic 5′ nuclease polymerase chain reaction (TaqMan) and mismatch amplification mutation assay. Mutat Res. 1999;430:1-12.